The tendency in monocytes from infected HD patients to reduce their CD86 and HLA-DR expression, which reduces their antigen presentation and co-stimulatory capacity, has been associated with severe COVID-19 [26,38,45] and could also partly explain the increased risk of severe outcome in chronic HD patients with COVID-19. This evidence concerns the gene CD86 and COVID-19.